3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Terminated
2
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Myelodysplastic Syndromes
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myeloid, Acute
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Lymphoma, Non-Hodgkin
4
Leukemia, Myelomonocytic, Juvenile
3
Multiple Myeloma
2
Lymphoma
2
Leukemia, Biphenotypic, Acute
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Breast Neoplasms
2
Shwachman-Diamond Syndrome
1
Sarcoma, Myeloid
1
Retinoblastoma
1
Primary Immunodeficiency Diseases
1
Neutropenia, Severe Congenital, Autosomal Recessive 3
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Medulloblastoma
1
Macrophage Activation Syndrome
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Large Granular Lymphocytic
1
Leukemia
1
Histiocytosis, Langerhans-Cell
1
Histiocytosis
1
Hemoglobinopathies
1
Bone Marrow Failure Disorders
1
Interventions
Vincristine
3
Etoposide
3
Carboplatin
3
Cyclophosphamide
2
trioctyl phosphine oxide
1
pembrolizumab
1
pegfilgrastim
1
Topotecan
1
Thiotepa
1
Surveys and Questionnaires
1
Platinum Compounds
1
Observation
1
Mesna
1
Melphalan
1
Lasers, Semiconductor
1
Lasers
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Eye Enucleation
1
Drug Therapy
1
Doxorubicin
1
Cytapheresis
1
Cryotherapy
1
Brachytherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Retinoblastoma
×
Thiotepa
×
Clear all
NCT02870907
2026-01-07
RB SFCE 09
Institut Curie
Phase 2
Active not recruiting
195 enrolled